Novavax Inc announced that an initial one million doses of Nuvaxovid (NVX-CoV2373) COVID-19 vaccine are now available in the U.K.
Nuvaxovid is the first protein-based COVID-19 vaccine granted authorization from the Medicines and Healthcare products Regulatory Agency (MHRA). It will be offered per the Joint Committee on Vaccination and Immunisation (JCVI) advice.
The MHRA granted Conditional Marketing Authorization for Nuvaxovid's use as a two-dose primary series vaccine in adults aged 18 and older in February 2022 and adolescents aged 12 through 17 in August 2022.
In August, FDA also granted expanded use authorization for Novavax's COVID-19 vaccine in adolescents.
Novavax submitted a request to the MHRA for expanded CMA of Nuvaxovid as a booster in adults aged 18 and older in June and is awaiting a decision from the agency.
Nuvaxovid is the first protein-based COVID-19 vaccine granted authorization from the Medicines and Healthcare products Regulatory Agency (MHRA). It will be offered per the Joint Committee on Vaccination and Immunisation (JCVI) advice.
The MHRA granted Conditional Marketing Authorization for Nuvaxovid's use as a two-dose primary series vaccine in adults aged 18 and older in February 2022 and adolescents aged 12 through 17 in August 2022.
In August, FDA also granted expanded use authorization for Novavax's COVID-19 vaccine in adolescents.
Novavax submitted a request to the MHRA for expanded CMA of Nuvaxovid as a booster in adults aged 18 and older in June and is awaiting a decision from the agency.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.